Check out the new site at WM-NET.org
A new era for Waldenstrom’s research has arrived! IWMF is thrilled to share the launch of the WM-NET website.
This is a national collaboration of 24 leading U.S. academic medical centers advancing translational research and innovative clinical trials for Waldenstrom macroglobulinemia.
WM-NET was established in 2024 with a simple premise: accelerating progress in Waldenstrom macroglobulinemia requires shared vision, shared data, and shared scientific leadership.
WM-NET coordinates a portfolio of multi-center clinical trials investigating next-generation therapies for Waldenstrom macroglobulinemia: there are currently 5 active clinical trials.
WM-NET’s leadership includes its founding director, Dr. Jorge Castillo (Dana-Farber Cancer Institute), and a national team of investigators representing 24 leading academic medical centers.
Supported by the International Waldenstrom Macroglobulinemia Foundation (IWMF) and rooted in long-standing collaborative relationships, WM-NET unifies leading clinicians and researchers to address the most important unanswered questions in WM care.
WM-NET is strengthened by the active involvement of the IWMF. The WM-Net leadership team includes Paul Kitchen, Chairman of the IWMF Board, and David Schnell, MD, Trustee and Chair of the Research Strategy Committee. Their participation reflects a shared commitment to aligning scientific and clinical priorities with the needs of the WM community.
This is more than a website; it’s a hub for cutting-edge, innovative trials and actionable research. Explore WM-NET’s mission, participating medical centers, and current studies at WM-NET.org. Additional updates related to WM-NET clinical studies, research milestones, and consortium activities will be shared here as they become available.
Read more about Clinical Trials.
Read more about IWMF’s Research Strategy.